AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Post-Traumatic Stress Disorder (PTSD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 - ResearchAndMarkets.com

August 29, 2018 GMT

DUBLIN--(BUSINESS WIRE)--Aug 29, 2018--The “Post-Traumatic Stress Disorder (PTSD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Post-Traumatic Stress Disorder (PTSD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 report provides comprehensive insights about marketed and Phase III products for Post-Traumatic Stress Disorder (PTSD). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Post-Traumatic Stress Disorder (PTSD) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ names along with their locations.

This report provides a comprehensive understanding of the emerging Phase III therapies for Post-Traumatic Stress Disorder (PTSD) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Post-Traumatic Stress Disorder (PTSD): Overview

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

5. Emerging Therapies (Phase III)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bfhjwz/posttraumatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180829005700/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Health,Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/29/2018 03:12 PM/DISC: 08/29/2018 03:12 PM

http://www.businesswire.com/news/home/20180829005700/en